Denis G Sukhodolsky1, Douglas W Woods2, John Piacentini2, Sabine Wilhelm2, Alan L Peterson2, Lily Katsovich2, James Dziura2, John T Walkup2, Lawrence Scahill2. 1. From Yale University School of Medicine (D.G.S., L.K., J.D.), New Haven, CT; Marquette University (D.W.W.), Milwaukee, WI; University of California at Los Angeles Geffen School of Medicine (J.P.); Massachusetts General Hospital/Harvard Medical School (S.W.), Boston; University of Texas Health Science Center at San Antonio (A.L.P.); Weill Cornell Medical College (J.T.W.), New York, NY; and Marcus Autism Center (L.S.), Emory University School of Medicine, Atlanta, GA. denis.sukhodolsky@yale.edu. 2. From Yale University School of Medicine (D.G.S., L.K., J.D.), New Haven, CT; Marquette University (D.W.W.), Milwaukee, WI; University of California at Los Angeles Geffen School of Medicine (J.P.); Massachusetts General Hospital/Harvard Medical School (S.W.), Boston; University of Texas Health Science Center at San Antonio (A.L.P.); Weill Cornell Medical College (J.T.W.), New York, NY; and Marcus Autism Center (L.S.), Emory University School of Medicine, Atlanta, GA.
Abstract
OBJECTIVE: To examine moderators and predictors of response to behavior therapy for tics in children and adults with Tourette syndrome and chronic tic disorders. METHODS: Data from 2 10-week, multisite studies (1 in children and 1 in adults; total n = 248) comparing comprehensive behavioral intervention for tics (CBIT) to psychoeducation and supportive therapy (PST) were combined for moderator analyses. Participants (177 male, 71 female) had a mean age of 21.5 ± 13.9 years (range 9-69). Demographic and clinical characteristics, baseline tic-suppressing medication, and co-occurring psychiatric disorders were tested as potential moderators for CBIT vs PST or predictors of outcome regardless of treatment assignment. Main outcomes measures were the Yale Global Tic Severity Scale Total Tic score and the Clinical Global Impression-Improvement score assessed by masked evaluators. RESULTS: The presence of tic medication significantly moderated response to CBIT vs PST (p = 0.01). Participants showed tic reduction after CBIT regardless of tic medication status, but only participants receiving tic medication showed reduction of tics after PST. Co-occurring psychiatric disorders, age, sex, family functioning, tic characteristics, and treatment expectancy did not moderate response. Across both treatments, greater tic severity (p = 0.005) and positive participant expectancy (p = 0.01) predicted greater tic improvement. Anxiety disorders (p = 0.042) and premonitory urge severity (p = 0.005) predicted lower tic reduction. CONCLUSIONS: Presence of co-occurring attention-deficit/hyperactivity disorder, obsessive-compulsive disorder, or anxiety disorders did not moderate response to CBIT. Although participants on tic medication showed improvement after CBIT, the difference between CBIT and PST was greater for participants who were not on tic-suppressing medication. CLINICALTRIALSGOV IDENTIFIERS: The child and adult CBIT studies are listed on clinical trials.gov (NCT00218777 and NCT00231985, respectively). CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that CBIT is effective in reducing tic severity across subgroups of patients with chronic tic disorders, although the difference between treatments was smaller for participants on tic-suppressing medications, suggesting reduced efficacy in this subgroup.
OBJECTIVE: To examine moderators and predictors of response to behavior therapy for tics in children and adults with Tourette syndrome and chronic tic disorders. METHODS: Data from 2 10-week, multisite studies (1 in children and 1 in adults; total n = 248) comparing comprehensive behavioral intervention for tics (CBIT) to psychoeducation and supportive therapy (PST) were combined for moderator analyses. Participants (177 male, 71 female) had a mean age of 21.5 ± 13.9 years (range 9-69). Demographic and clinical characteristics, baseline tic-suppressing medication, and co-occurring psychiatric disorders were tested as potential moderators for CBIT vs PST or predictors of outcome regardless of treatment assignment. Main outcomes measures were the Yale Global Tic Severity Scale Total Tic score and the Clinical Global Impression-Improvement score assessed by masked evaluators. RESULTS: The presence of tic medication significantly moderated response to CBIT vs PST (p = 0.01). Participants showed tic reduction after CBIT regardless of tic medication status, but only participants receiving tic medication showed reduction of tics after PST. Co-occurring psychiatric disorders, age, sex, family functioning, tic characteristics, and treatment expectancy did not moderate response. Across both treatments, greater tic severity (p = 0.005) and positive participant expectancy (p = 0.01) predicted greater tic improvement. Anxiety disorders (p = 0.042) and premonitory urge severity (p = 0.005) predicted lower tic reduction. CONCLUSIONS: Presence of co-occurring attention-deficit/hyperactivity disorder, obsessive-compulsive disorder, or anxiety disorders did not moderate response to CBIT. Although participants on tic medication showed improvement after CBIT, the difference between CBIT and PST was greater for participants who were not on tic-suppressing medication. CLINICALTRIALSGOV IDENTIFIERS: The child and adult CBIT studies are listed on clinical trials.gov (NCT00218777 and NCT00231985, respectively). CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that CBIT is effective in reducing tic severity across subgroups of patients with chronic tic disorders, although the difference between treatments was smaller for participants on tic-suppressing medications, suggesting reduced efficacy in this subgroup.
Authors: Joseph F McGuire; Epiphanie Nyirabahizi; Katharina Kircanski; John Piacentini; Alan L Peterson; Douglas W Woods; Sabine Wilhelm; John T Walkup; Lawrence Scahill Journal: Psychiatry Res Date: 2013-09-27 Impact factor: 3.222
Authors: Bret R Rutherford; Joel R Sneed; Jane M Tandler; David Rindskopf; Bradley S Peterson; Steven P Roose Journal: J Am Acad Child Adolesc Psychiatry Date: 2011-06-15 Impact factor: 8.829
Authors: John Piacentini; Douglas W Woods; Lawrence Scahill; Sabine Wilhelm; Alan L Peterson; Susanna Chang; Golda S Ginsburg; Thilo Deckersbach; James Dziura; Sue Levi-Pearl; John T Walkup Journal: JAMA Date: 2010-05-19 Impact factor: 56.272
Authors: Scott N Compton; Tara S Peris; Daniel Almirall; Boris Birmaher; Joel Sherrill; Phillip C Kendall; John S March; Elizabeth A Gosch; Golda S Ginsburg; Moira A Rynn; John C Piacentini; James T McCracken; Courtney P Keeton; Cynthia M Suveg; Sasha G Aschenbrand; Dara Sakolsky; Satish Iyengar; John T Walkup; Anne Marie Albano Journal: J Consult Clin Psychol Date: 2014-01-13
Authors: Sabine Wilhelm; Alan L Peterson; John Piacentini; Douglas W Woods; Thilo Deckersbach; Denis G Sukhodolsky; Susanna Chang; Haibei Liu; James Dziura; John T Walkup; Lawrence Scahill Journal: Arch Gen Psychiatry Date: 2012-08
Authors: Susanna W Chang; Joseph F McGuire; John T Walkup; Douglas W Woods; Lawrence Scahill; Sabine Wilhelm; Alan L Peterson; James Dziura; John Piacentini Journal: Psychiatry Res Date: 2018-01-02 Impact factor: 3.222
Authors: Helen B Murray; Adrienne S Juarascio; Carlo Di Lorenzo; Douglas A Drossman; Jennifer J Thomas Journal: Am J Gastroenterol Date: 2019-04 Impact factor: 10.864
Authors: Jeremy M Raines; Kimberly R Edwards; Martin F Sherman; Christopher I Higginson; Joel B Winnick; Kelly Navin; Julie M Gettings; Fatmata Conteh; Shannon M Bennett; Matthew W Specht Journal: J Neural Transm (Vienna) Date: 2017-11-28 Impact factor: 3.575
Authors: Joseph F McGuire; Emily J Ricketts; Lawrence Scahill; Sabine Wilhelm; Douglas W Woods; John Piacentini; John T Walkup; Alan L Peterson Journal: Psychol Med Date: 2019-08-27 Impact factor: 7.723
Authors: Tamara Pringsheim; Michael S Okun; Kirsten Müller-Vahl; Davide Martino; Joseph Jankovic; Andrea E Cavanna; Douglas W Woods; Michael Robinson; Elizabeth Jarvie; Veit Roessner; Maryam Oskoui; Yolanda Holler-Managan; John Piacentini Journal: Neurology Date: 2019-05-07 Impact factor: 11.800
Authors: Christine A Conelea; Brianna Wellen; Douglas W Woods; Deanna J Greene; Kevin J Black; Matthew Specht; Michael B Himle; Han-Joo Lee; Matthew Capriotti Journal: Front Psychiatry Date: 2018-05-23 Impact factor: 4.157